Physician profile
Mark Dawson
NPI 1457322133
$8,704.67
in general payments reported to CMS, 2019-2025
38 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,305 · 2020: $450 · 2021: $1,198 · 2022: $1,454 · 2023: $1,498 · 2024: $1,494 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,257 · Education: $40.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,257.20 |
| Education | $40.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,781.05 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $668.70 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $622.81 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $538.58 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $515.37 | 2019-2025 | Epclusa |
| Pfizer INC. | $432.86 | 2019-2025 | |
| Qol Medical, LLC | $360.33 | 2023-2024 | Sucraid, Sucraid |
| Boston Scientific Corporation | $295.65 | 2019-2025 | Endoarmor, Axios, Axonics |
| Madrigal Pharmaceuticals | $255.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $249.34 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $210.06 | 2019-2024 | Linzess |
| Genzyme Corporation | $177.95 | 2023-2025 | |
| Amgen INC. | $155.65 | 2023-2025 | Uplizna, Avsola, Amjevita |
| Intuitive Surgical, INC. | $133.18 | 2025 | |
| Intercept Pharmaceuticals, INC. | $129.71 | 2020-2025 | Ocaliva |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $121.47 | 2019-2024 | Dificid, Zinplava |
| Nestle Healthcare Nutrition INC. | $101.57 | 2021-2023 | |
| Cook Medical LLC | $96.18 | 2019 | |
| Phathom Pharmaceuticals, INC. | $94.62 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $91.46 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $91.46 | 2022-2024 | Dupixent |
| Palette Life Sciences, INC. | $88.95 | 2022 | |
| Ucb, INC. | $71.05 | 2019-2021 | |
| Allergan, INC. | $65.56 | 2019 | |
| Redhill Biopharma INC. | $63.09 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Lilly USA, LLC | $60.39 | 2024 | Omvoh |
| Braintree Laboratories, INC. | $36.72 | 2022-2024 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $33.79 | 2022-2023 | Rebyota |
| Covidien LP | $21.68 | 2019 | |
| Ardelyx, INC. | $18.34 | 2023 | Ibsrela |
| Aimmune Therapeutics, INC. | $17.37 | 2024 | |
| Shionogi INC | $16.72 | 2019 | |
| Alfasigma USA, INC. | $16.39 | 2020 | |
| Organon LLC | $15.04 | 2025 | Hadlima, Renflexis |
| Vivus LLC | $14.74 | 2024 | Pancreaze |
| Novo Nordisk INC | $14.35 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.26 | 2024 | Givlaari |
| Olympus America INC. | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.